NEW ASPECTS OF TREATMENT OF CHRONIC HEART FAILURE: FOCUS ON ANTAGONISTS OF MINERALOCORTICOID RECEPTORS
Introduction. The article presents evidence of the efficacy and safety of the use of receptor blockers aldosterone, which were obtained in the implementation of several randomized clinical trials. Presents the first experience of application of the selective antagonist of mineralocorticoid receptors in clinical practice.
The aim of the study was to assess the effect of the antagonist of mineralocorticoid receptors of eplerenone on the functional state of patients with heart failure, dynamics of the LV ejection fraction and the concentration of brain natriuretic peptide in the blood.
Results and conclusions: the study included 21 men (70%) and 9 women (30%) the average age of the patients was 57,9 ± 3,3 years. All patients had a detailed clinical picture of heart failure, functional class NYHA of CHF were III (56%) and IV (44%). In the primary analysis of the data of echocardiography, the average left ventricular ejection fraction was 37,5 ± 2,7 per cent. Brain natriuretic peptide (BNP) were determined selectively, examinees was average BNP – 475,7 ± 3,9 pg/ml. At the control examination, the average LVEF was 45,4 ± 1,5%, and the average creatinine and potassium was 108 ± 2,1 mcmol/l and 5,2 ± 0,9 mmol/l respectively.
Conclusion: AMS is an obligatory component of therapy of CHF. Eplerenone showed its effectiveness in improving functional status, increasing LV EF in patients with CHF decompensation.
Key words: heart failure, antagonist of mineralocorticoid receptors, ejection fraction.
Lyudmila K.Karazhanova 1, http://orcid.org/0000-0002-4719-6034
Merhat R. Nasymbekov 2
Oksana Khaidarova 2
Andrey Yu. Orekhov 1
Marzhan M. Ospanova 1
1 Department of therapy internship,
Semey State Medical University,
Semey, Kazakhstan;
2 Emergency hospital,
Semey c., Kazakhstan.
Rеfеrеncеs:
1. Gilyarevskii C.R., Orlov V.A., Kuz'mina I.M., Golshmid M.V., Zakharova G.Yu., Sinitsina I.I. Dokazatel'nye osnovy primeneniya eplerenona [Evidence-based use of Eplerenone]. Klinitsist. [The Clinician]. 2012. Vol. 6. № 1. pp 81-85. http://klinitsist.abvpress.ru/Klin/article/view/75 (Дата обращения: 17.05.2017). [in Russian]
2. Gegenava B.B., Drapkina O.M. Selektivnyi antagonist mineralokortikoidnykh retseptorov v kardiologicheskoi praktike [A selective antagonist of mineralocorticoid receptor in cardiology practice] Ratsional'naya farmakoterapiya v kardiologii. [Rational Pharmacotherapy in Cardiology] 2015. Vol 11, № 2. pp. 177-181. [in Russian] http://www.rpcardio.com/jour/article/view/146 (Дата обращения: 22.05.2017)
3. Grzhibovskii A.M., Ivanov S.V., Gorbatova M.A. Opisatelnaya statistika s ispolzovaniem paketov statisticheskikh programm Statistica i SPSS [Descriptive statistics using packages Statistica and SPSS statistical software]. Nauka i Zdravookhranenie [Science & Healthcare]. 2016. №1. pp. 7-23. [in Russian]
4. Grjibovski A.M., Ivanov S.V. Kogortnye issledovaniya v zdravookhranenii [Cohort studies in health sciences]. Nauka i Zdravookhranenie [Science & Healthcare]. 2015, 3, pp. 5-16. [in Russian]
5. Grjibovski A.M., Ivanov S.V. Poperechnye (odnomomentnye) issledovanoya v zdravookhranenii [Cross-sectional studies in health sciences]. Nauka i Zdravookhranenie [Science & Healthcare]. 2015, No2, pp. 5-18. [in Russian]
6. Karazhanova L.K. Diagnostika i lechenie khronicheskoi serdechnoi nedostatochnosti [Diagnosis and treatment of chronic heart failure]. Nauka i zdravookhranenie [Science & Healthcare]. 2012. №2. pp. 33-38. [in Russian]
7. Mareev V. Yu., Fomin I. V., Ageev F. T., Arutyunov G. P., Begrambekova Yu. L., Belenkov Yu. N. i dr. Klinicheskie rekomendatsii. Khronicheskaya serdechnaya nedostatochnost' (KhSN) [Clinical guidelines. Chronic heart failure (CHF)] Zhurnal Serdechnaya Nedostatochnost' [Russian Heart Failure Journal] 2017. Vol 18. №1. pp. 3–40. [in Russian]
8. Ponikowski P., A. Voors A., D. Anker S., Bueno H., Cleland J., J. S . Coats A., Falk V., González-Juanatey J., Harjola V., A. Jankowska E., Jessup M., Linde C., Nihoyannopoulos P.T., Parissis J., Pieske B., P. Riley J., M. C. Rosano G., M. Ruilope L., Ruschitzka F., H. Rutten F., van der Meer P. Rekomendatsii ESC po diagnostike i lecheniyu ostroi i khronicheskoi serdechnoi nedostatochnosti. 2016 [2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure]. Rossiiskii kardiologicheskii zhurnal [Russian Journal of Cardiology]. 2017. № 1. pp. 7-81. [in Russian]
9. Ahmed A., Blackman M.R., White M., Anker S.D. Emphasis on abdominal obesity as a modifier of eplerenone effect in heart failure: hypothesis-generating signals from EMPHASIS-HF. European Journal of Heart Failure. 2017. May 30.
10. Connell J. Aldosterone — the future challenge in cardiovascular disease? The British Journal of Diabetes and Vascular Disease. 2004. № 4. pp. 370−376
11. Davies J.O., Freeman R.H. Historical perspectives on the renin-angiotensinaldosterone system and angiotensin blockade. Journal of the American College of Cardiology. 1982. № 49. pp. 1385−1389
12. Delcayre C., Swynghedauw B. Molecular mechanisms of myocardial remodeling: the role of aldosterone. Journal of Molecular and Cellular Cardiology. 2002. № 34. pp. 1577-1584.
13. Ezekowitz J.A., McAlister F.A. Aldosterone blockade and left ventricular dysfunction: a systematic reviewof randomized clinical trials. European Heart Journal. 2009. № 30. pp. 469-477.
14. Faiez Zannad, John J.V. McMurray, Henry Krum, Dirk J. van Veldhuisen, Karl Swedberg, Harry Shi, John Vincent, Stuart J. Pocock, and Bertram Pitt, for the EMPHASIS-HF Study Group. Eplerenone in Patients with Systolic Heart Failure and Mild Symptom. The New England Journal of Medicine. 2011. № 1. pp. 11—21
15. Fullerton M.J., Funder J.W. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovascular Research. 1994. № 28. pp. 1863-1867.
16. Hayashi M., Tsutamoto T., Wada A., et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003. Vol. 107. pp 2559-2565
17. Iraqi W., Rossignol P., Angioi M., et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation. 2009. Vol 119. pp 2471-2479.
18. Jessup M., Abraham W.T., Casey D.E., et al. 2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009. Vol. 119. hh. 1977-2016.
19. McKelvie R.S., Yusuf S., Pericak D., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. Circulation. 1999. Vol. 100. pp. 1056-1064.
20. Libby P., Bonow R.O., Mann D., Zipes D.P.. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Eighth Edition. Philadelphia. 2008. Vol 2. pp 623
21. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. The New England Journal of Medicine. 2003; Vol 348. pp. 1309-1321.
22. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patientswith severe heart failure: Randomized Aldactone Evaluation Study Investigators. The New England Journal of Medicine. 1999. Vol 341. pp. 709-17.
23. Pitt B., Williams G., Remme W., et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovascular Drugs and Therapy. 2001. Vol. 15, №1. pp. 79-87.
24. Swedberg K.1., Zannad F., McMurray J.J., et al.; EMPHASIS-HF Study Investigators. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. Journal of the American College of Cardiology. 2012. Vol. 59. № 18. pp. 1598-1603
25. Zannad F., McMurray J.V., Krum H., et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. The New England Journal of Medicine. Vol. 364. pp. 11-21.
Bibliography link
Karazhanova L.K., Nasymbekov M.R., Khaidarova O.V., Orekhov A.Yu., Ospanova M.M. New aspects of treatment of chronic heart failure: focus on antagonists of mineralocorticoid receptors. Nauka i Zdravookhranenie [Science & Healthcare]. 2017, 6, pp. 88-100.